• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于重组组织型纤溶酶原激活剂在新型冠状病毒肺炎中应用的观察性研究表明生理死腔减少。

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.

作者信息

Orfanos Sarah, El Husseini Ibrahim, Nahass Thomas, Radbel Jared, Hussain Sabiha

机构信息

Dept of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Both authors contributed equally to this work.

出版信息

ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00455-2020. eCollection 2020 Oct.

DOI:10.1183/23120541.00455-2020
PMID:33043052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7533378/
Abstract

https://bit.ly/2GdM44a.

摘要

https://bit.ly/2GdM44a. （此为网址，无法准确翻译出完整意思，保留原文即可）

相似文献

1
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.关于重组组织型纤溶酶原激活剂在新型冠状病毒肺炎中应用的观察性研究表明生理死腔减少。
ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00455-2020. eCollection 2020 Oct.
2
Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS.估算的死腔量可能与 COVID-19 所致 ARDS 的 28 天死亡率无关。
Crit Care. 2021 May 17;25(1):171. doi: 10.1186/s13054-021-03570-0.
3
COVID-19 ARDS Is Characterized by Increased Dead Space Ventilation Compared With Non-COVID ARDS.COVID-19 导致的急性呼吸窘迫综合征（ARDS）的特点是死腔通气量增加，与非 COVID-19 导致的 ARDS 相比。
Respir Care. 2021 Sep;66(9):1406-1415. doi: 10.4187/respcare.08786. Epub 2021 May 25.
4
Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.重组组织型纤溶酶原激活剂治疗 COVID-19 相关的 ARDS 和急性肺心病。
Int J Infect Dis. 2021 Mar;104:108-110. doi: 10.1016/j.ijid.2020.12.043. Epub 2021 Jan 13.
5
Relationship between D-dimers and dead-space on disease severity and mortality in COVID-19 acute respiratory distress syndrome: A retrospective observational cohort study.D-二聚体与 COVID-19 急性呼吸窘迫综合征疾病严重程度和死亡率的关系：一项回顾性观察队列研究。
J Crit Care. 2023 Oct;77:154313. doi: 10.1016/j.jcrc.2023.154313. Epub 2023 Apr 26.
6
Increased physiological dead space in mechanically ventilated COVID-19 patients recovering from severe acute respiratory distress syndrome: a case report.机械通气的 COVID-19 患者在严重急性呼吸窘迫综合征康复过程中生理性死腔增加：病例报告。
BMC Infect Dis. 2020 Aug 27;20(1):637. doi: 10.1186/s12879-020-05360-5.
7
Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Eur Heart J. 1998 Oct;19(10):1518-24. doi: 10.1053/euhj.1998.1092.
8
Association of dead space fraction to mortality in patients with COVID-19-related ARDS: A historical cohort observational study.新冠肺炎相关 ARDS 患者死腔分数与死亡率的相关性：一项历史队列观察性研究。
Med Intensiva (Engl Ed). 2024 Nov;48(11):639-645. doi: 10.1016/j.medine.2024.06.009. Epub 2024 Jun 21.
9
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.由弥漫性肺血栓和对溶栓有反应的肺内皮功能障碍驱动的COVID-19危重病病理生理学。
Clin Transl Med. 2020 Jun;10(2):e44. doi: 10.1002/ctm2.44. Epub 2020 Jun 5.
10
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.组织型纤溶酶原激活物（tPA）治疗 COVID-19 相关急性呼吸窘迫综合征（ARDS）：病例系列。
J Thromb Haemost. 2020 Jul;18(7):1752-1755. doi: 10.1111/jth.14828. Epub 2020 May 11.

引用本文的文献

1
Nebulized alteplase in coronavirus disease 2019 pneumonia: a case series.COVID-19 肺炎中雾化用阿替普酶：病例系列。
J Med Case Rep. 2024 Nov 28;18(1):572. doi: 10.1186/s13256-024-04924-2.
2
Systemic thrombolytics as rescue therapy for COVID-19 patients with acute respiratory distress syndrome: A retrospective observational study.全身性溶栓剂作为新型冠状病毒肺炎急性呼吸窘迫综合征患者的挽救治疗：一项回顾性观察研究。
Int J Crit Illn Inj Sci. 2022 Oct-Dec;12(4):197-203. doi: 10.4103/ijciis.ijciis_45_22. Epub 2022 Dec 26.
3
Effectiveness and safety of fibrinolytic therapy in critically ill patients with COVID-19 with ARDS: protocol for a prospective meta-analysis.

本文引用的文献

1
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
2
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.组织型纤溶酶原激活剂治疗严重 COVID-19 相关急性呼吸窘迫综合征的抢救治疗：病例系列研究。
J Trauma Acute Care Surg. 2020 Sep;89(3):453-457. doi: 10.1097/TA.0000000000002786.
3
Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.
新冠肺炎合并急性呼吸窘迫综合征危重症患者溶栓治疗的有效性和安全性：一项前瞻性荟萃分析方案。
BMJ Open. 2022 Sep 26;12(9):e063855. doi: 10.1136/bmjopen-2022-063855.
4
MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.组织纤溶酶原激活剂（阿替普酶）用于新型冠状病毒肺炎严重呼吸衰竭的多中心研究（MUST COVID）：一项回顾性队列研究。
Res Pract Thromb Haemost. 2022 Mar 21;6(2):e12669. doi: 10.1002/rth2.12669. eCollection 2022 Feb.
5
Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial.SARS-CoV-2 相关 COVID-19 呼吸衰竭患者应用阿替普酶的研究：一项先锋性、快速适应、实用、随机对照试验。
Chest. 2022 Mar;161(3):710-727. doi: 10.1016/j.chest.2021.09.024. Epub 2021 Sep 27.
6
Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.组织型纤溶酶原激活剂用于重症 COVID-19 成年患者
Ann Am Thorac Soc. 2021 Nov;18(11):1917-1921. doi: 10.1513/AnnalsATS.202102-127RL.
7
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.靶向纤溶酶原激活物抑制剂-1在 COVID-19 中的治疗潜力。
Trends Pharmacol Sci. 2021 Jun;42(6):431-433. doi: 10.1016/j.tips.2021.03.006. Epub 2021 Mar 26.
8
Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.重组组织型纤溶酶原激活剂治疗 COVID-19 相关的 ARDS 和急性肺心病。
Int J Infect Dis. 2021 Mar;104:108-110. doi: 10.1016/j.ijid.2020.12.043. Epub 2021 Jan 13.
对新冠病毒疾病（COVID-19）患者的尸检显示，肺部出现弥漫性肺泡损伤，伴有严重的毛细血管充血，肺部及其他器官呈现出多样化的表现，提示存在血管功能障碍。
Histopathology. 2020 Aug;77(2):198-209. doi: 10.1111/his.14134. Epub 2020 Jul 5.
4
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.急性呼吸窘迫综合征（ARDS）中的纤维蛋白溶解异常和溶栓药物治疗 COVID-19 的多功能性。
J Thromb Haemost. 2020 Jul;18(7):1548-1555. doi: 10.1111/jth.14872. Epub 2020 Jun 3.
5
Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?组织型纤溶酶原激活剂作为难治性新型冠状病毒肺炎相关急性呼吸窘迫综合征的一种新型治疗方法，是否具有作用？
J Trauma Acute Care Surg. 2020 Jun;88(6):713-714. doi: 10.1097/TA.0000000000002694.
6
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.组织型纤溶酶原激活物（tPA）治疗 COVID-19 相关急性呼吸窘迫综合征（ARDS）：病例系列。
J Thromb Haemost. 2020 Jul;18(7):1752-1755. doi: 10.1111/jth.14828. Epub 2020 May 11.
7
Power to mechanical power to minimize ventilator-induced lung injury?将动力转换为机械能以最小化呼吸机相关性肺损伤？
Intensive Care Med Exp. 2019 Jul 25;7(Suppl 1):38. doi: 10.1186/s40635-019-0243-4.
8
Dead space in acute respiratory distress syndrome.急性呼吸窘迫综合征中的死腔
Ann Transl Med. 2018 Oct;6(19):388. doi: 10.21037/atm.2018.09.46.
9
Physiologic Analysis and Clinical Performance of the Ventilatory Ratio in Acute Respiratory Distress Syndrome.急性呼吸窘迫综合征通气比的生理分析与临床性能。
Am J Respir Crit Care Med. 2019 Feb 1;199(3):333-341. doi: 10.1164/rccm.201804-0692OC.
10
Fibrinolysis and the control of blood coagulation.纤维蛋白溶解与血液凝固的控制
Blood Rev. 2015 Jan;29(1):17-24. doi: 10.1016/j.blre.2014.09.003. Epub 2014 Sep 16.